Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person When bound to the high-affinity IgE receptor (FCERI), IgE ac...
| Class:Id | Summation:9725209 |
|---|---|
| _displayName | When bound to the high-affinity IgE receptor (FCERI), IgE ac... |
| _timestamp | 2021-03-29 08:56:28 |
| created | [InstanceEdit:9725211] Stephan, Ralf, 2021-03-29 |
| text | When bound to the high-affinity IgE receptor (FCERI), IgE acts as an environmental sensor that detects allergens and induces allergic responses from the cell's interior. Omalizumab is a monoclonal antibody that binds free IgE preventing it from binding to FCERI. Moreover, reduction of free IgE concentrations reduce FCERI expression level. Omalizumab is approved for the treatment of patients with severe allergic asthma. Use of omalizumab is associated with several side effects, including injection site reactions, viral and upper respiratory tract infections, headache, sinusitis, and pharyngitis. The main severe adverse effect is anaphylactic shock, with a rate of occurrence of 1 to 2 patients per 1,000 (Davydov 2005, Arm et al. 2014). |
| (summation) | [Reaction:9724685] IgE binds omalizumab [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by When bound to the high-affinity IgE receptor (FCERI), IgE ac... (9725209)
